journal article·2021-11-17

Yolk–Shell-Type Gold Nanoaggregates for Chemo- and Photothermal Combination Therapy for Drug-Resistant Cancers

Hyun-Seok Choe, Min Joo Shin, Seong Gyu Kwon, Haklae Lee, Dae Kyoung Kim, Kyung Un Choi, Jae-Hyuk Kim, Jae Ho Kim

ACS Applied Materials & Interfaces· Volume 13· Issue 45
Publisher page

Abstract

Epithelial ovarian cancer is a gynecological cancer with the highest mortality rate, and it exhibits resistance to conventional drugs. Gold nanospheres have gained increasing attention over the years as photothermal therapeutic nanoparticles, owing to their excellent biocompatibility, chemical stability, and ease of synthesis; however, their practical application has been hampered by their low colloidal stability and photothermal effects. In the present study, we developed a yolk–shell-structured silica nanocapsule encapsulating aggregated gold nanospheres (aAuYSs) and examined the photothermal effects of aAuYSs on cell death in drug-resistant ovarian cancers both in vitro and in vivo. The aAuYSs were synthesized using stepwise silica seed synthesis, surface amino functionalization, gold nanosphere decoration, mesoporous organosilica coating, and selective etching of the silica template. Gold nanospheres were agglomerated in the confined silica interior of aAuYSs, resulting in the red-shifting of absorbance and enhancement of the photothermal effect under 808 nm laser irradiation. The efficiency of photothermal therapy was first evaluated by inducing aAuYS-mediated cell death in A2780 ovarian cancer cells, which were cultured in a two-dimensional culture and a three-dimensional spheroid culture. We observed that photothermal therapy using aAuYSs together with doxorubicin treatment synergistically induced the cell death of doxorubicin-resistant A2780 cancer cells in vitro. Furthermore, this type of combinatorial treatment with photothermal therapy and doxorubicin synergistically inhibited the in vivo tumor growth of doxorubicin-resistant A2780 cancer cells in a xenograft transplantation model. These results suggest that photothermal therapy using aAuYSs is highly effective in the treatment of drug-resistant cancers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Environmental Engineering, Pusan National University, Busan 46241, Republic of Korea

Department of Physiology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Department of Pathology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Funding

National Research Foundation of Korea · Pusan National University

References (50)

Show source-provided references
1. 10.1093/annonc/mdx44110.1093/annonc/mdx441 ↗
2. 10.1002/jcp.2628910.1002/jcp.26289 ↗
3. 10.1007/s11912-001-0038-z10.1007/s11912-001-0038-z ↗
4. 10.1186/s13045-020-00931-010.1186/s13045-020-00931-0 ↗
5. 10.2174/138161282566619101416392310.2174/1381612825666191014163923 ↗
6. 10.1039/c9nh00628a10.1039/c9nh00628a ↗
7. 10.1021/acsnano.8b0145610.1021/acsnano.8b01456 ↗
8. 10.1021/acsami.8b1349210.1021/acsami.8b13492 ↗
9. 10.20517/cdr.2020.2010.20517/cdr.2020.20 ↗
10. 10.1016/j.colsurfb.2017.09.04510.1016/j.colsurfb.2017.09.045 ↗
11. 10.1021/acsami.7b1732310.1021/acsami.7b17323 ↗
12. 10.1016/j.actbio.2018.09.01710.1016/j.actbio.2018.09.017 ↗
13. 10.1021/acsami.7b1600010.1021/acsami.7b16000 ↗
14. 10.1002/adfm.20200018910.1002/adfm.202000189 ↗
15. 10.1039/d0tb00093k10.1039/d0tb00093k ↗
16. 10.1021/acs.bioconjchem.0c0013510.1021/acs.bioconjchem.0c00135 ↗
17. 10.1039/c0cs00018c10.1039/c0cs00018c ↗
18. 10.1038/8668410.1038/86684 ↗
19. 10.1021/jp409067h10.1021/jp409067h ↗
20. 10.1039/c4ra02978j10.1039/c4ra02978j ↗
21. 10.1016/j.solener.2013.12.00410.1016/j.solener.2013.12.004 ↗
22. 10.1038/srep2983610.1038/srep29836 ↗
23. 10.1039/c6nr00056h10.1039/c6nr00056h ↗
24. 10.1039/c5nr04729c10.1039/c5nr04729c ↗
25. 10.1002/smll.20200231110.1002/smll.202002311 ↗
26. 10.1021/nn401168610.1021/nn4011686 ↗
27. 10.1039/df951110005510.1039/df9511100055 ↗
28. 10.1016/0021-9797(68)90272-510.1016/0021-9797(68)90272-5 ↗
29. 10.1021/ar400091e10.1021/ar400091e ↗
30. 10.1186/s11671-016-1576-510.1186/s11671-016-1576-5 ↗
31. 10.1039/c7cp03876c10.1039/c7cp03876c ↗
32. 10.1021/cr068028210.1021/cr0680282 ↗
33. 10.1080/0144235005003418010.1080/01442350050034180 ↗
34. 10.1002/adma.20160489410.1002/adma.201604894 ↗
35. 10.1126/sciadv.abb002010.1126/sciadv.abb0020 ↗
36. 10.1016/j.jcis.2015.11.01710.1016/j.jcis.2015.11.017 ↗
37. 10.1021/nn101079210.1021/nn1010792 ↗
38. 10.1039/c0an00366b10.1039/c0an00366b ↗
39. 10.1002/smll.20090043410.1002/smll.200900434 ↗
40. 10.1038/s41598-018-30541-310.1038/s41598-018-30541-3 ↗
41. 10.1155/2012/73439810.1155/2012/734398 ↗
42. 10.1038/emm.2016.7310.1038/emm.2016.73 ↗
43. 10.1111/bph.1410410.1111/bph.14104 ↗
44. 10.1038/s41586-019-1730-110.1038/s41586-019-1730-1 ↗
45. 10.1021/acs.nanolett.0c0065010.1021/acs.nanolett.0c00650 ↗
46. 10.3390/cancers704087710.3390/cancers7040877 ↗
47. 10.1002/adma.20080092110.1002/adma.200800921 ↗
48. 10.1016/s1470-2045(02)00818-510.1016/s1470-2045(02)00818-5 ↗
49. 10.1002/smll.20190050110.1002/smll.201900501 ↗
50. 10.3390/cancers1203063410.3390/cancers12030634 ↗